ATE503485T1 - Zusammensetzung mit mindestens einem nukleosidteil als heilmittel sowie ckc - Google Patents

Zusammensetzung mit mindestens einem nukleosidteil als heilmittel sowie ckc

Info

Publication number
ATE503485T1
ATE503485T1 AT07301550T AT07301550T ATE503485T1 AT E503485 T1 ATE503485 T1 AT E503485T1 AT 07301550 T AT07301550 T AT 07301550T AT 07301550 T AT07301550 T AT 07301550T AT E503485 T1 ATE503485 T1 AT E503485T1
Authority
AT
Austria
Prior art keywords
composition
ckc
cure
nucleoside portion
nucleoside
Prior art date
Application number
AT07301550T
Other languages
English (en)
Inventor
Gregory Lambert
Frederic Lallemand
Original Assignee
Novagali Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novagali Pharma Sa filed Critical Novagali Pharma Sa
Application granted granted Critical
Publication of ATE503485T1 publication Critical patent/ATE503485T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
AT07301550T 2007-11-14 2007-11-14 Zusammensetzung mit mindestens einem nukleosidteil als heilmittel sowie ckc ATE503485T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07301550A EP2060262B1 (de) 2007-11-14 2007-11-14 Zusammensetzung mit mindestens einem Nukleosidteil als Heilmittel sowie CKC

Publications (1)

Publication Number Publication Date
ATE503485T1 true ATE503485T1 (de) 2011-04-15

Family

ID=39451279

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07301550T ATE503485T1 (de) 2007-11-14 2007-11-14 Zusammensetzung mit mindestens einem nukleosidteil als heilmittel sowie ckc

Country Status (3)

Country Link
EP (1) EP2060262B1 (de)
AT (1) ATE503485T1 (de)
DE (1) DE602007013574D1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU753270B2 (en) * 1998-05-21 2002-10-10 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
EP1469009A2 (de) 1998-05-21 2004-10-20 Isis Parmaceuticals, Inc. Zusammensetzungen und Verfahren für nicht-parenterale Verabreichung von Oligonukleotiden
US8168600B2 (en) 2004-04-23 2012-05-01 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
EP1891939B1 (de) * 2006-07-28 2013-09-11 Novagali Pharma S.A. Zusamensetzungen die quaternäre Ammonium Verbindungen enthalten

Also Published As

Publication number Publication date
EP2060262B1 (de) 2011-03-30
EP2060262A1 (de) 2009-05-20
DE602007013574D1 (de) 2011-05-12

Similar Documents

Publication Publication Date Title
CY1112259T1 (el) Συνθεσεις οι οποιες περιλαμβανουν ορνιθινη και φαινυλοξικο ή φαινυλοβουτυρικο για αντιμετωπιση ηπατικης εγκεφαλοπαθειας
BRPI0815322B8 (pt) "componente de conexão para respirador e máscara para proteção respiratória"
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
DK2219642T3 (da) Silibininbestandel til behandling af hepatitis
HK1129594A1 (en) Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain
BRPI0909768A2 (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
WO2009067397A3 (en) Treatment for solid tumors
BRPI0616982B8 (pt) uso de oligouronato, composição farmacêutica inalável e aplicador de spray
BRPI0817384A2 (pt) "método para a fabricação de um dispositivo, dispositivo para inalação e dispositivo ou componente"
IL160420A0 (en) Treating or preventing diabetes with cannabidiol
BRPI0713447A2 (pt) composição forma de dosagem oral sólida, e, método para o tratamento de dor
BRPI0910495A2 (pt) "formulação, método de tratamento de plantas, método de aumento da eficácia de uma formulação, herbicida, e, uso de uma mistura"
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
UA94580C2 (ru) Аналог 39-дезметоксирапамицина, способный преодолевать гематоэнцефалический барьер, для лечения патологического состояния, вызванного нейрогенным повреждением или заболеванием
WO2008076257A3 (en) Treating cancer with anti-igflr antibody 19d12 = sch 717454
WO2006047631A3 (en) Anti-mitotic anti-proliferative compounds
HK1137352A1 (en) Therapeutic use of at least one botulic neurotoxin in the treatment of pain induced by at least one antineoplastic agent
BRPI0905687A2 (pt) "composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto"
CY1110658T1 (el) Χρηση του καρραγηνου για τη θεραπεια μολυνσεων απο ρινοϊο
BRPI0703970A2 (pt) tratamento de pacientes psiquiátricos com função hepática reduzida com paliperidona
BRPI0806529A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties